{"id":944847,"date":"2026-03-16T17:46:51","date_gmt":"2026-03-16T21:46:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/"},"modified":"2026-03-16T17:46:51","modified_gmt":"2026-03-16T21:46:51","slug":"veracyte-names-kevin-haas-as-chief-development-and-technology-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/","title":{"rendered":"Veracyte Names Kevin Haas as Chief Development and Technology Officer"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Veracyte Names Kevin Haas as Chief Development and Technology Officer<\/b><\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=54448269&amp;newsitemid=20260316934398&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc&amp;index=1&amp;md5=70fe99cff1ad6b4aca76a91de18f769f\">Veracyte, Inc<\/a>. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company\u2019s global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company\u2019s end\u2011to\u2011end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260316934398\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260316934398\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 343px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260316934398\/en\/2747035\/4\/KevinHaas.jpg\" alt=\"Veracyte Names Kevin Haas as Chief Development and Technology Officer\" \/><\/p>\n<p style=\"font-size:85%\">Veracyte Names Kevin Haas as Chief Development and Technology Officer<\/p>\n<\/div>\n<p>\nAs Veracyte\u2019s pipeline expands into whole\u2011genome minimal residual disease (MRD) and other multi\u2011omics applications, product development requires integrated capabilities across assays, software, AI, and next\u2011generation informatics to support solutions from diagnosis to disease management. In this role, Dr. Haas will lead these efforts to deliver high\u2011quality laboratory\u2011developed tests (LDTs) and global in vitro diagnostic (IVD) products. He will bring these capabilities together to accelerate innovation and support the company\u2019s global portfolio.<\/p>\n<p>\n\u201cKevin is an accomplished product development and software leader with a track record of advancing diagnostic innovations and platform technologies,\u201d said Marc Stapley, Veracyte\u2019s Chief Executive Officer. \u201cHis experience across software engineering, data science, and assay development will be critical as we execute on a growing pipeline of tests in development and expand our portfolio to benefit clinicians and patients worldwide.\u201d<\/p>\n<p>\nDr. Haas has more than 15 years of life sciences industry experience, leading teams across technology, research, and development. Most recently, he served as Chief Technology Officer at Myriad Genetics, where he led the development of the company\u2019s precision medicine platform and digital health strategy. Prior to that, Dr. Haas was Senior Vice President of Engineering at Myriad and Vice President of Bioinformatics at Myriad Women&#8217;s Health. Before joining Myriad, he held leadership roles in lab engineering and bioinformatics at Counsyl.<\/p>\n<p>\nDr. Haas has expertise in creating automated lab technology and AI systems to derive insights from genomics data, and in launching scalable molecular assays. He received a B.S. from University of Wisconsin-Madison and a Ph.D. in chemical engineering from University of California-Berkeley, where he worked on molecular simulation and machine learning to study protein dynamics.<\/p>\n<p>\n\u201cI am excited to join Veracyte at a time when the company is launching several exciting new tests, which is just the start of an incredibly strong development pipeline,\u201d said Dr. Haas. \u201cThe opportunity to help advance this breadth of innovation and development capabilities by bringing new diagnostic solutions for patients facing cancer is incredibly meaningful.\u201d<\/p>\n<p><b>About Veracyte<\/b><\/p>\n<p>\nVeracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com&amp;esheet=54448269&amp;newsitemid=20260316934398&amp;lan=en-US&amp;anchor=www.veracyte.com&amp;index=2&amp;md5=c59850f8aad656e5a05eeae8feb48cce\">www.veracyte.com<\/a> or follow us on LinkedIn or X (Twitter).<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: \u201cappears,\u201d &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; \u201cpositioned,\u201d \u201cdesigned\u201d and similar references to future periods. Additional factors that may impact these forward-looking statements can be found under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed on February 26, 2026, and our subsequent Quarterly Reports on Form 10-Q. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260316934398r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260316934398\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260316934398\/en\/<\/a><\/span><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Shayla Gorman<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@veracyte.com\">investors@veracyte.com<\/a><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Molly Cornbleet<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@veracyte.com\">media@veracyte.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology General Health Health Artificial Intelligence Infectious Diseases Health Technology Technology Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260316934398\/en\/2747035\/3\/KevinHaas.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Veracyte Names Kevin Haas as Chief Development and Technology Officer<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260316934398\/en\/791654\/3\/Veracyte_RGB_LRG_H_registered.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Veracyte Names Kevin Haas as Chief Development and Technology Officer SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company\u2019s global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company\u2019s end\u2011to\u2011end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260316934398\/en\/ Veracyte Names Kevin Haas as Chief Development and Technology Officer As Veracyte\u2019s pipeline expands into whole\u2011genome minimal residual disease (MRD) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Veracyte Names Kevin Haas as Chief Development and Technology Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-944847","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Veracyte Names Kevin Haas as Chief Development and Technology Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte Names Kevin Haas as Chief Development and Technology Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Veracyte Names Kevin Haas as Chief Development and Technology Officer SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company\u2019s global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company\u2019s end\u2011to\u2011end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260316934398\/en\/ Veracyte Names Kevin Haas as Chief Development and Technology Officer As Veracyte\u2019s pipeline expands into whole\u2011genome minimal residual disease (MRD) &hellip; Continue reading &quot;Veracyte Names Kevin Haas as Chief Development and Technology Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T21:46:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260316934398\/en\/2747035\/4\/KevinHaas.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veracyte Names Kevin Haas as Chief Development and Technology Officer\",\"datePublished\":\"2026-03-16T21:46:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/\"},\"wordCount\":805,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316934398\\\/en\\\/2747035\\\/4\\\/KevinHaas.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/\",\"name\":\"Veracyte Names Kevin Haas as Chief Development and Technology Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316934398\\\/en\\\/2747035\\\/4\\\/KevinHaas.jpg\",\"datePublished\":\"2026-03-16T21:46:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316934398\\\/en\\\/2747035\\\/4\\\/KevinHaas.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316934398\\\/en\\\/2747035\\\/4\\\/KevinHaas.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte Names Kevin Haas as Chief Development and Technology Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte Names Kevin Haas as Chief Development and Technology Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte Names Kevin Haas as Chief Development and Technology Officer - Market Newsdesk","og_description":"Veracyte Names Kevin Haas as Chief Development and Technology Officer SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company\u2019s global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company\u2019s end\u2011to\u2011end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260316934398\/en\/ Veracyte Names Kevin Haas as Chief Development and Technology Officer As Veracyte\u2019s pipeline expands into whole\u2011genome minimal residual disease (MRD) &hellip; Continue reading \"Veracyte Names Kevin Haas as Chief Development and Technology Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-16T21:46:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260316934398\/en\/2747035\/4\/KevinHaas.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veracyte Names Kevin Haas as Chief Development and Technology Officer","datePublished":"2026-03-16T21:46:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/"},"wordCount":805,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260316934398\/en\/2747035\/4\/KevinHaas.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/","name":"Veracyte Names Kevin Haas as Chief Development and Technology Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260316934398\/en\/2747035\/4\/KevinHaas.jpg","datePublished":"2026-03-16T21:46:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260316934398\/en\/2747035\/4\/KevinHaas.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260316934398\/en\/2747035\/4\/KevinHaas.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-names-kevin-haas-as-chief-development-and-technology-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veracyte Names Kevin Haas as Chief Development and Technology Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/944847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=944847"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/944847\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=944847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=944847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=944847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}